We’re thrilled to announce our participation at World Orphan Drug Congress Europe 2024, taking place in Barcelona this October. Below, you can learn more about our team members who will be attending, discover our booth’s location in the exhibition hall, book a meeting with us, and get a glimpse of our program at the event.
Our daily summaries and post-conference report is available at the bottom of this page.
About the conference
The World Orphan Drug Congress is a leading global event dedicated to the advancement of orphan drugs and rare diseases. Held annually, the congress brings together a diverse group of stakeholders, including industry leaders, researchers, patient advocates, and policymakers, to discuss the latest developments in the field. The congress provides a platform for collaboration, innovation, and knowledge-sharing, with a focus on improving the diagnosis, treatment, and care of rare disease patients.
Featuring a comprehensive agenda that covers key topics such as drug development, regulatory challenges, market access, and patient engagement, the World Orphan Drug Congress plays a crucial role in shaping the future of orphan drug development and ensuring that patients with rare diseases receive the attention and support they deserve.
Say hello
Remap Consulting will have an Exhibition Booth (Booth 62) in exhibition hall 2 at the conference, where you’ll always be able to find one of team and learn more about how we can help you solve your pricing and market access challenges to enable improved patient access in the rare disease space. Please come along and say hi!
Our team
We’re pleased to present our conference team this year, with expertise spanning a wide range of areas, including health economics, RWE, market access, and HTA.
If you’d like to arrange a meeting with any of our attendees at the conference then please contact us here. Plus, connect with our team on LinkedIn.
Our programme of events
We’re delighted to have the opportunity to host a panel discussion on the “Access & Pricing” track and present the below research at WODC this year, and we look forward to many engaging conversations with you.
| Date | Event | Time | Team Member |
| All days | Research by Remap Consulting: 1) Are NICE Achieving Their Timelines for Reviewing HSTs in England? 2) Comparing And Contrasting Early Access Opportunities Across Four Nordic Countries | 1:30 pm on Wednesday 23 Oct, 12:40 pm on Thursday 24 Oct and 12:10 pm on Friday 25 Oct. | Amy Boyers Solen Monteil Theia Kwong |
| 24th October | A panel discussion by Remap Consulting: Access & Pricing track: Strategic Evidence Generation: Exploring Multiple Stakeholder Needs | 11.10 – 11.55 am | Mariam Bibi |
Panel discussion: Strategic Evidence Generation
Meet our moderator, Practice Lead at Remap Consulting:
Mariam Bibi has over 15 years of experience in evidence generation for Market Access and healthcare decision-making across public and private sectors, including roles at the Northwest Public Health Observatory and NICE. She has developed RWE capabilities, provided strategic evidence-generation advice, and led HEOR projects. Mariam has also served as an Associate Lecturer in Epidemiology, External Advisor to NICE, and member of the NHS technical linkage group. She holds a BSc in Microbiology, a PhD in Epidemiology, and is a Senior Associate at the Royal Society of Medicine.
Meet our panellists:
Ruth Pulikottil Jacob is the EMEA HEOR Lead at Cepheid. She has over 15 years of experience in healthcare, HEOR, and market access, including leading strategies for rare disease products at Sanofi. Ruth has held roles as an academic researcher, member of the NICE evidence review group, and NHS positions. She has authored 65+ peer-reviewed articles and holds a PhD in Health Economics from the University of Warwick and an MPH from the University of Sheffield.
Andrew Olaye is General Manager, UK and Ireland as well as the Head of EMEA Market Access at Orchard Therapeutics. Having led several market access and reimbursement activities across Europe, Middle East and Africa, Andrew has gained extensive experience in launching innovative therapies in different markets.
Daniel de Vicente is the President of ASMD Spain with over 20 years of experience as a community pharmacist and project developer for patient organisations. As founder of Advocacy360 Consulting, he specialises in strategic planning and programme development to empower patient involvement in decision-making and real-world evidence projects. He also serves on the boards of FEDER and Eurordis.
Josie Godfrey is a Director at JG Zebra Consulting and an independent consultant with 15 years of experience in rare diseases and innovative therapies. She is the Strategic Director for Duchenne UK’s Project HERCULES and Global Access Lead for Project Mercury. Josie is also joint CEO of Realise Advocacy, currently co-leading the evaluation of England’s Rare Disease Action Plan, and previously led NICE’s Highly Specialised Technologies programme.
Congress Insights
Just like in past years, Remap Consulting have crafted daily summaries of the keynote sessions. Read the key takeaways below.
Panel Discussion by Remap Consulting
Full report below.